Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
NoteHC Andersen Capital receives payment from ALK-Abelló for a DigitalIR/Corporate Visibility agreement. See disclaimer.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

ALK-Abelló

148.6

 

DKK

 

+1.36 %

Less than 1K followers

ALK B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
+1.36%
+4.28%
-0.4%
-6.6%
-13.86%
+15.55%
+3.41%
+79.9%
+330.72%

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.

Read more
Market cap
33.11B DKK
Turnover
24.2M DKK
Revenue
5.54B
EBIT %
19.7 %
P/E
40.38
Dividend yield-%
-
Financial calendar
6.5
2025

Interim report Q1'25

21.8
2025

Interim report Q2'25

13.11
2025

Interim report Q3'25

All
Research
Webcasts
Press releases
ShowingAll content types
ALK – Præsentation af Q1 2025
Webcast5/8/2025, 8:30 AM

ALK – Præsentation af Q1 2025

Mød og stil spørgsmål til ALK EVP og CFO Claus Steensen Sølje og VP & Head of IR Per Plotnikof d. 8. maj kl. 10.30. Investorerne kan forvente en finansiel gennemgang af udviklingen i årets første kvartal 2024. ALK har fået en række godkendelser af sin husstøvmideallergi tablet til børn i alderen 3-11 år, i UK, Canada og USA.

ALK-Abelló
Regulatory press release4/3/2025, 2:23 PM

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

ALK-Abelló
Regulatory press release4/3/2025, 2:23 PM

Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere

ALK-Abelló

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/13/2025, 5:06 PM

Generalforsamling i ALK-Abelló A/S afholdt den 13. marts 2025

ALK-Abelló
Regulatory press release3/13/2025, 5:06 PM

Annual General Meeting in ALK-Abelló A/S held on 13 March 2025

ALK-Abelló
Press release3/7/2025, 1:34 PM

ACARIZAX® approved in Canada for treatment of young children

ALK-Abelló
Regulatory press release3/4/2025, 9:20 PM

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK-Abelló
Regulatory press release3/4/2025, 9:20 PM

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK-Abelló
Regulatory press release2/27/2025, 8:51 PM

Den amerikanske lægemiddelmyndighed (FDA) godkender ODACTRA® til behandling af husstøvmideallergi hos yngre børn

ALK-Abelló
Regulatory press release2/27/2025, 8:51 PM

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

ALK-Abelló
Dagens aktienyheder 25/02: Skako, Agillic og ALK
Analyst Comment2/25/2025, 8:02 AM

Dagens aktienyheder 25/02: Skako, Agillic og ALK

Dagens aktienyheder med Skako, Agillic og ALK

SKAKOAgillicALK-Abelló
ALK: Wrap up fra interview med CFO Claus Steensen Sølje og Head of IR Per Plotnikof
Analyst Comment2/25/2025, 7:20 AM by
Claus Thestrup

ALK: Wrap up fra interview med CFO Claus Steensen Sølje og Head of IR Per Plotnikof

ALK: Wrap up fra interview med CFO Claus Steensen Sølje og Head of IR Per Plotnikof

ALK-Abelló
ALK – Præsentation af årsregnskabet 2024
Webcast2/24/2025, 12:00 PM

ALK – Præsentation af årsregnskabet 2024

Mød og stil spørgsmål til ALK’s EVP og CFO Claus Steensen Sølje og VP & Head of IR Per Plotnikof mandag d. 24. februar kl. 13.00. Investorerne kan forvente en finansiel gennemgang af udviklingen i årets sidste kvartal 2024, og en opdatering på hvad de skal forvente sig i 2025.

ALK-Abelló
Regulatory press release2/21/2025, 2:59 PM

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK-Abelló
Regulatory press release2/21/2025, 2:59 PM

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK-Abelló
Regulatory press release2/19/2025, 1:46 PM

Ordinær generalforsamling i ALK-Abelló A/S den 13. marts 2025

ALK-Abelló
Regulatory press release2/19/2025, 1:46 PM

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

ALK-Abelló
Regulatory press release2/19/2025, 6:32 AM

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

ALK-Abelló
Press release2/12/2025, 4:02 PM

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK-Abelló
Press release2/12/2025, 4:02 PM

Invitation til præsentation af ALK’s årsrapport for 2024 onsdag den 19. februar 2025

ALK-Abelló
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.